Biotest AG
Biotest AG: Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R)
DGAP-News: Biotest AG / Key word(s): Research Update / Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R) – The development of donor specific antibodies (DSA) can lead to graft rejection and thus to a greatly increased mortality risk – To date no convincing therapy concept for treatment of DSA after lung transplantation available – Relative reduction in mortality by more than 70% after Pentaglobin(R) therapy after one year – Four years of data on Pentaglobin(R) therapy show promise for long-term therapy success
In the Pentaglobin(R) group (128 patients) the survival rate of 94% after one year was comparable to patients without DSA (452 patients) and much higher than in the historic therapeutic plasma exchange group (57 patients with DSA development) with a survival rate of 79%. The relative mortality rate after one year was reduced more than 70%. “IgM-enriched immunoglobulin eliminates the mortality risk caused by DSA after lung transplantation. Data from four years, which has now been published, show that there are no significant differences in the treated patient population, which previously had donor specific antibodies, compared to patients, who did not develop donor specific antibodies”, stated Professor Dr Gregor Warnecke, principal investigator for the study. The particular importance of Pentaglobin(R) therapy is evident in an indirect comparison with similar data from a French study, in which the patient population was treated with standard immunoglobulins. Despite standard immunoglobulin administration, the DSA-positive patients had a much lower survival rate than patients without DSA (41% vs. 70% after 5 years).[3] Biotest is the sole manufacturer of IgM-enriched immunoglobulin worldwide. These promising results indicate a breakthrough in organ rejection therapy and support the Pentaglobin(R) approach to transplantation. Promising data on Pentaglobin(R) therapy after heart transplantation is available. About Pentaglobin(R) About Biotest IR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer
29.05.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |